Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;35(9):e546-e548.
doi: 10.1111/jdv.17342. Epub 2021 May 29.

Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine

B M Cyrenne  1 , F Al-Mohammedi  1 , J G DeKoven  1 , R Alhusayen  1
Affiliations

Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine

B M Cyrenne et al. J Eur Acad Dermatol Venereol. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Clinical findings of pityriasis rosea‐like eruption in the patients. (a) Patient 1: Thin red to tan oval plaques with peripheral scale on the trunk. (b) Patient 1: Close‐up of a plaque. (c) Patient 2: Thin red to tan oval plaques with peripheral scale on the trunk and proximal thigh. (d) Patient 2: Close‐up of plaques, with the hyperpigmented centre and trailing scale.
Figure 2
Figure 2
Histopathological findings of pityriasis rosea‐like eruption in patient 1. Parakeratosis with minimal acanthosis and spongiosis of the epidermis. Few scattered dyskeratotic keratinocytes are seen in the lower epidermis. The papillary dermis shows melanin incontinence, perivascular lymphocytic infiltrate and rare scattered extravasated red blood cells. (a) haematoxylin‐eosin, original magnification ×10. (b) haematoxylin‐eosin, original magnification ×20.
See this image and copyright information in PMC

References

    1. Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue. Br J Dermatol 2020; 183: 431–442. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med 2020; 383: 2603–2615. - PMC - PubMed
    1. Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea‐like eruptions: how to distinguish them? JAAD Case Rep 2018; 4: 800–801. - PMC - PubMed
    1. Drago F, Ciccarese G, Javor S, Parodi A. Vaccine‐induced pityriasis rosea and pityriasis rosea‐like eruptions: a review of the literature. J Eur Acad Dermatol Venereol 2016; 30: 544–545. - PubMed
    1. Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus‐6, ‐7, and Epstein‐Barr virus reactivation in pityriasis rosea during COVID‐19. J Med Virol 2021; 93: 1850–1851. - PMC - PubMed